Komori
General Meetings of Shareholders4536SANTEN PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Notice of Convocation of the 2026 Annual General Meeting of Shareholders and Meeting Materials

The materials set out the holding of the 114th Annual General Meeting of Shareholders and seek shareholders’ approval for the appropriation of surplus and the election of 7 directors. The slate comprises 6 directors for re-election and 1 new outside director.

Worth reading
58In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
7
Number of director candidates
Wording
Definitive
How definitive the wording is.

Resolutions for the General Meeting of Shareholders

Annual, 114th fiscal year
2026
Jun 23
Date and time(Tuesday), 10:00 a.m. (registration opens at 9:00 a.m.)28 days from this disclosure to the meeting
Matters for resolution2 items
  1. Appropriation of surplus

  2. Election of 7 Directors

Shareholder Proposal

No

A shareholder proposal is a resolution submitted by a shareholder, rather than by the company.
Director nominee
7Nominees
1New
4Outside
Resolutions for the General Meeting of Shareholders
ItemDetails
Type of shareholders' meetingAnnual, 114th fiscal year
Date and time23 June 2026 (Tuesday), 10:00 a.m. (registration opens at 9:00 a.m.)
Matters for resolutionProposal 1: Appropriation of surplus, Proposal No. 2: Election of 7 Directors
Shareholder ProposalNo
Director nominee7 candidates, including 1 new candidate and 4 outside directors
Items this document does not state (1)
Percentage voting in favor

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To welcome a new outside director with an understanding of the life sciences business and clinical settings, as well as knowledge of global management, in order to enhance the Board of Directors’ oversight function and the quality of its discussions.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Convocation of the 2026 Annual General Meeting of Shareholders and Meeting Materials | SANTEN PHARMACEUTICAL CO.,LTD. (4536) timely disclosure | Komori